17.97
전일 마감가:
$17.64
열려 있는:
$17.52
하루 거래량:
2.07M
Relative Volume:
1.21
시가총액:
$1.60B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-6.4289
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
+1.64%
1개월 성능:
-8.18%
6개월 성능:
-25.19%
1년 성능:
+19.72%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals Inc
|
17.97 | 1.60B | 217.42M | -243.25M | -278.35M | -2.7952 |
|
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals stock holds recent gains as investor conferences and cancer drug outlook draw - AD HOC NEWS
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Syndax Pharmaceuticals stock gains on investor conference schedule and steady September trading - AD HOC NEWS
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com
Two talks by Syndax executives will be webcast live from New York in September. - Stock Titan
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat
Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains - Investing.com India
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
Syndax Pharmaceuticals Inc. (SNDX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Syndax stock gains attention as investor conferences approach - ad-hoc-news.de
Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Alyeska Investment Group L.P. Acquires Shares of 308,507 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Announces Participation in September Investor Conferences - GlobeNewswire
Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of New York Mellon Corp Makes New $22.74 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Q2 2026 Earnings: Wider-than-Expected EPS Loss Triggers Share DeclineEarnings Manipulation Risk - vinanet.vn
Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus
UBS lowers Syndax Pharmaceuticals price target on revenue outlook - Investing.com
UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating - finance.yahoo.com
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress
Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - careplusvn.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Breakeven? - news.futunn.com
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
SNDX Stock Price, Quote & Chart - ChartMill
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):